Holen Sie sich die Stockscreener-App
463.22
2.95%
13.26
Handel nachbörslich:
463.22
Schlusskurs vom Vortag:
$449.96
Offen:
$445.42
24-Stunden-Volumen:
2.13M
Relative Volume:
1.45
Marktkapitalisierung:
$100.29B
Einnahmen:
$76.39B
Nettoeinkommen (Verlust:
$7.81B
KGV:
15.93
EPS:
29.0772
Netto-Cashflow:
$7.93B
1W Leistung:
+0.83%
1M Leistung:
+7.08%
6M Leistung:
+7.25%
1J Leistung:
-0.69%
1-Tages-Spanne:
$445.00
$466.08
1-Wochen-Bereich:
$439.83
$488.00
52-Wochen-Spanne:
$353.99
$556.52
Hca Healthcare Inc Stock (HCA) Company Profile
Firmenname
Hca Healthcare Inc
Sektor
Branche
Telefon
(615) 344-9551
Adresse
ONE PARK PLZ, NASHVILLE, TN
Compare HCA vs THC, EHC, FMS, DVA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HCA
Hca Healthcare Inc
|
463.22 | 100.29B | 76.39B | 7.81B | 7.93B | 29.08 |
THC
Tenet Healthcare Corp
|
268.50 | 21.62B | 21.46B | 2.65B | 3.35B | 19.23 |
EHC
Encompass Health Corp
|
122.09 | 12.04B | 6.07B | 793.80M | 464.40M | 5.9914 |
FMS
Fresenius Medical Care Ag Adr
|
22.62 | 12.04B | 22.44B | 1.35B | 2.03B | 1.9002 |
DVA
Davita Inc
|
183.93 | 11.73B | 13.84B | 1.10B | 1.49B | 10.42 |
Hca Healthcare Inc Stock (HCA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-23 | Eingeleitet | BMO Capital Markets | Outperform |
| 2026-07-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2025-10-14 | Fortgesetzt | Goldman | Buy |
| 2025-07-28 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-07-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-29 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2025-04-15 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-12-17 | Fortgesetzt | JP Morgan | Neutral |
| 2024-11-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2024-11-22 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-10-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2024-09-03 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-05-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-06 | Eingeleitet | Barclays | Overweight |
| 2024-01-04 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-12-11 | Herabstufung | Goldman | Buy → Neutral |
| 2023-04-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-19 | Fortgesetzt | JP Morgan | Neutral |
| 2022-07-06 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2022-06-17 | Eingeleitet | Loop Capital | Buy |
| 2022-05-27 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-29 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-01-10 | Fortgesetzt | Citigroup | Buy |
| 2021-12-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-09-27 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-24 | Eingeleitet | UBS | Buy |
| 2021-09-10 | Eingeleitet | Cowen | Outperform |
| 2021-08-12 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-07-09 | Eingeleitet | Seaport Global Securities | Buy |
| 2021-05-13 | Fortgesetzt | Citigroup | Neutral |
| 2021-04-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-15 | Eingeleitet | Goldman | Buy |
| 2020-12-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-09-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-09-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-10 | Hochstufung | Goldman | Neutral → Buy |
| 2019-04-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-01-14 | Eingeleitet | Stephens | Overweight |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Buy |
| 2018-11-16 | Eingeleitet | UBS | Buy |
| 2018-03-23 | Fortgesetzt | Mizuho | Buy |
| 2018-01-03 | Eingeleitet | Goldman | Neutral |
| 2018-01-03 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-12-20 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2017-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2017-11-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-11-06 | Bestätigt | Citigroup | Neutral |
| 2017-11-01 | Bestätigt | Mizuho | Buy |
| 2017-07-26 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2017-06-28 | Eingeleitet | Argus | Buy |
Alle ansehen
Hca Healthcare Inc Aktie (HCA) Neueste Nachrichten
HCA Healthcare Q3 Earnings Beat Estimates on Higher Admissions - Zacks Investment Research
HCA (HCA) Reports Q3 Earnings: What Key Metrics Have to Say - Zacks Investment Research
HCA Healthcare beats Q3 estimates, stock jumps By Investing.com - Investing.com Nigeria
HCA: Q3 Earnings Snapshot - WWLTV.com
RBC raises target for HCA Healthcare stock from USD 435 to USD 496 - ad-hoc-news.de
HCA Healthcare beats quarterly profit estimates on demand for medical services - Reuters
HCA Healthcare beats quarterly profit estimates on demand for medical services - Yahoo Finance Singapore
HCA Healthcare Reports Third Quarter 2026 Results - Business Wire
HCA Healthcare, Inc. $HCA Stock: Valley National Advisers Inc. Trims Stake - MarketBeat
HCA Healthcare, Inc. $HCA Stock Bought by Hourglass Capital LLC - MarketBeat
Stock Market Today, Oct. 26: Surgery Partners Skyrockets 48% on $5.7 Billion HealthSpan Acquisition - The Motley Fool
HCA Healthcare (HCA) Set to Report Q3 Earnings Amid Slight Valua - GuruFocus
HCA Healthcare sets October 27 results date: 22 analysts rate HCA Healthcare stock Buy - ad-hoc-news.de
HCA Healthcare earnings in focus amid Medicaid headwinds - Investing.com
2 Beaten-Down Healthcare Stocks to Buy and Hold for the Next Decade - The Motley Fool
Why Investors Need to Take Advantage of These 2 Medical Stocks Now - Zacks Investment Research
TD Cowen raises target for HCA Healthcare stock from USD 431 to USD 460 - ad-hoc-news.de
HCA Healthcare earnings: what to look for from HCA - FinancialContent
HCA Healthcare, Inc. $HCA Stock Holdings Lowered by Robeco Institutional Asset Management B.V. - MarketBeat
HCA Healthcare, Inc. $HCA Stock: Investment House LLC Lowers Position - MarketBeat
HCA Healthcare Q3 2026 Earnings Preview — October 27, Street Expects $6.63 EPS - AlphaStreet
Establishment Labs Holdings Inc. (ESTA) Expected to Beat Earnings Estimates: Should You Buy? - Zacks Investment Research
Will HCA Healthcare's Q3 Earnings Benefit From Higher Admissions? - Yahoo Finance
HCA Healthcare, Inc. $HCA Shares Sold by Eagle Rock Investment Company LLC - MarketBeat
HCA Healthcare, Inc. $HCA Stock Sold by Cooke & Bieler LP - MarketBeat
HCA Healthcare Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
HCA Healthcare to Host Eighth Annual “Crush the Crisis” National Prescription Drug Take Back Day - Florida Hospital News and Healthcare Report
Danaher (DHR) Tops Q3 Earnings and Revenue Estimates - Zacks Investment Research
HCA Healthcare Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
HCA Healthcare Inc (2BH.DU) stock price, news, quote and history - Yahoo Finance UK
Analysts Estimate HCA Healthcare (HCA) to Report a Decline in Earnings: What to Look Out for - Zacks Investment Research
Analysts Estimate HCA Healthcare (HCA) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Here's How Much a $1000 Investment in HCA Healthcare Made 10 Years Ago Would Be Worth Today - Yahoo Finance
HCA Healthcare (HCA) Expected to Announce Earnings on Tuesday - MarketBeat
Lobbying Update: $750,000 of HCA HEALTHCARE INC. lobbying was just disclosed - Quiver Quantitative
HCA Healthcare Foundation Awards $25,000 to Waypoint to Expand the Network of Adults Supporting Youth Mental Wellness Across Virginia - GlobeNewswire Inc.
HCA Healthcare Inc. stock outperforms competitors despite losses on the day - MarketWatch
HCA Healthcare Inc. stock outperforms competitors on strong trading day - MarketWatch
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HCA Healthcare, Inc. – HCA - GlobeNewswire Inc.
Joint Commission Enterprise Names Ken Grubbs, DNP, MBA, RN, Chief Operating Officer - GlobeNewswire Inc.
HCA Healthcare (HCA) Stock Could Trade At A Discount Following Its 96% Run - Yahoo Finance
HCA Healthcare Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Take the Zacks Approach to Beat the Markets: HF Sinclair, Accenture & FirstCash in Focus - Zacks Investment Research
HCA Healthcare Inc. stock outperforms competitors on strong trading day - MarketWatch
WBO:HCAH Dividend: Does HCA Healthcare Inc Pay a Dividend? - GuruFocus
Should You Be Adding HCA Healthcare (NYSE:HCA) To Your Watchlist Today? - Moomoo
HCA Healthcare, Inc. $HCA Shares Sold by Bell Asset Management Ltd - MarketBeat
HCA Healthcare Inc. stock outperforms competitors on strong trading day - MarketWatch
HCA Healthcare stock stands at EUR 396.50 with USD 96.2 billion market value - AD HOC NEWS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HCA Healthcare, Inc.HCA - PR Newswire
Finanzdaten der Hca Healthcare Inc-Aktie (HCA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Hca Healthcare Inc-Aktie (HCA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Michael R McAlevey | OFFICER |
Feb 18 '26 |
Proposed Sale |
533.34 |
1,694 |
903,486 |
0 |
| McAlevey Michael R | EVP & Chief Legal & Admin Off. |
Feb 18 '26 |
Sale |
533.37 |
1,694 |
903,537 |
8,853 |
| Wyatt Christopher F. | SVP & Controller |
Feb 11 '26 |
Sale |
505.00 |
4,000 |
2,020,000 |
44,379 |
| Berres Jennifer | SVP & Chief Human Res. Officer |
Feb 11 '26 |
Sale |
514.58 |
8,020 |
4,126,950 |
11,993 |
| Jennifer L. Berres | OFFICER |
Feb 11 '26 |
Proposed Sale |
514.58 |
8,020 |
4,126,950 |
0 |
| Wyatt Christopher F. | SVP & Controller |
Feb 05 '26 |
Option Exercise |
139.06 |
10,670 |
1,483,770 |
51,737 |
| Foster Jon M | EVP and COO |
Feb 05 '26 |
Option Exercise |
139.06 |
29,330 |
4,078,630 |
29,330 |
| Cuffe Michael S. | EVP and Chief Clinical Officer |
Feb 03 '26 |
Sale |
498.09 |
1,500 |
747,135 |
30,003 |
| HAZEN SAMUEL N | CEO |
Feb 03 '26 |
Sale |
501.04 |
42,877 |
21,483,275 |
32,276 |
| MICHAEL S CUFFE | OFFICER |
Feb 03 '26 |
Proposed Sale |
498.09 |
1,500 |
747,135 |
0 |
2.46%
2.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):